About US
Contact us
-
Samsung eyes manufacturing expansions into U.S. and beyond as work on Korean 'Super Plant' plows aheadSamsung Biologics was among a handful of manufacturers to enjoy a production boost during the COVID-19 pandemic. Now, as work on a "Super Plant" in its native South Korea progresses, the CDMO is draw2021/1/20
-
Woodcock to step up to interim FDA chief as she and Sharfstein are vetted for permanent job: reportsFDA veteran Janet Woodcock will take over as commissioner, at least temporarily, according to media reports, and former deputy FDA chief Joshua Sharfstein is at the top of the list for the permanent2021/1/18
-
Regeneron inks big new coronavirus antibody supply deal worth up to $2.6BPharma companies worldwide scrambled to respond to the COVID-19 pandemic early last year, but so faronly a few haveadvanced therapies and vaccines through to the market. Regeneron is one, and now the2021/1/18
-
What do Novartis deal, PD-1 competition in China mean for tislelizumab? Here's what BeiGene CEO has to sayBeiGene has had a few busy weeks. In its home base of China, the company won national reimbursement for three products. Outside of China, it just signed Novartis as a partner on immuno-oncology thera2021/1/15
-
Woodcock to step up to interim FDA chief as she and Sharfstein are vetted for permanent job: reportsFDA veteran Janet Woodcock will take over as commissioner, at least temporarily, according to media reports, and former deputy FDA chief Joshua Sharfstein is at the top of the list for the permanent2021/1/15
-
Merck pulls close to Pfizer in next-gen pneumococcal vaccine race as FDA fast-tracks 15-strain vaccinePfizer’s $5.8 billion-a-year Prevnar 13 is one of the company’s top blockbusters and the undisputed leader in the market for pneumococcal vaccines. But when it comes to the next generation of pneumon2021/1/13
-
JPM: Alexion gives an updated look at what AstraZeneca's getting for $39BToward the end of 2020, AstraZeneca splashed out $39 billion for Alexion to expand its immunology presence. That's a big price—and questions naturally followed about whether it was justified. Now, th2021/1/13
-
Look out, pharma. A 'tidal wave' of side effect reports is coming amid COVID-19 vaccine rolloutsWith COVID-19 vaccine launches gaining steam—and an unprecedented level of media coverage zeroed in—pharma companies of all stripes should brace not only for a wave of adverse event reports, experts2021/1/11
-
Should pharma charity contributions be publicly disclosed, just like doctor payments? Senators say yesPharma companies have inked a series of federal settlements over payments to charity organizations, which the federal government argues are a “conduit” to boosting drug sales. Now, after an opioid in2021/1/11
-
Catalent inks deal to offload blow-fill-seal business to SK CapitalNew Jersey CDMO Catalent made waves last year as it inked one COVID-19 vaccine manufacturing deal after another, all the while continuing its push into cell and gene therapy. Now, the manufacturer is2021/1/8